Viewing Company
Company Name:
ASLAN Pharmaceuticals Limited
CIK:
1722926
Phone:
None
Fiscal Year End:
None
Entity Type:
SIC:
-
Category Type:
Entity Name:
None
First Filing Date:
2019-04-29
Last Filing Date:
2024-04-12
SEC Filings
| Start | End | Frame | Filed | ACCN | Value | View |
|---|---|---|---|---|---|---|
| 2022-01-01 | 2022-06-30 | CY2022Q2I | 2022-08-12 | 0001193125-22-219243 | $ 16,543,352 | View |
| 2018-01-01 | 2018-12-31 | CY2018 | 2019-04-29 | 0001564590-19-013503 | $ 187,244 | View |
| 2021-02-01 | 2021-02-28 | CY2021 | 2022-03-25 | 0001564590-22-011742 | $ 18,000,000 | View |
| 2019-01-01 | 2019-09-30 | CY2017Q3I | 2019-10-31 | 0001193125-19-279593 | $ 160,248,940 | View |
| 2019-01-01 | 2019-12-31 | CY2017 | 2020-04-16 | 0001564590-20-016974 | $ 162,392,602 | View |
| 2020-01-01 | 2020-06-30 | CY2020Q2I | 2020-10-09 | 0001193125-20-267200 | $ 189,954,970 | View |
| 2020-01-01 | 2020-09-30 | CY2020Q3I | 2021-01-29 | 0001193125-21-022624 | $ 189,954,970 | View |
| 2020-01-01 | 2020-12-31 | CY2020 | 2021-04-23 | 0001564590-21-020241 | $ 192,226,528 | View |
| 2021-01-01 | 2021-06-30 | CY2011Q2I | 2021-08-06 | 0001193125-21-238543 | $ 302,985,377 | View |
| 2022-01-01 | 2023-06-30 | CY2023Q2I | 2023-08-11 | 0000950170-23-041592 | $ 12,000,000 | View |
| 2021-03-01 | 2021-03-31 | CY2021Q1I | 2024-04-12 | 0000950170-24-043860 | $ 64,900,000 | View |
| 2021-02-01 | 2021-02-28 | CY2021Q1I | 2023-03-24 | 0000950170-23-009599 | $ 18,000,000 | View |
SEC Facts By Type
| Type | Name | Description | View |
|---|---|---|---|
| ifrs-full | 1371383 | None | View |
| us-gaap | Other Income | Amount of revenue and income classified as other. | View |
| us-gaap | Proceeds from Issuance Initial Public Offering | The cash inflow associated with the amount received from entity's first offering of stock to the public. | View |
| dei | Entity Common Stock, Shares Outstanding | Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. | View |
| us-gaap | Proceeds from Issuance of Private Placement | The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. | View |